NCE-1 Intelligence & Market Opportunity

Pluvicto

Lutetium (177lu) Vipivotide Tetraxetan

Anticancer

Intravenous Solution

Approval Date

23-Mar-22

NCE-1 Date

23-Mar-26

NCE Date

23-Mar-27

Commercial snapshot

Market performance & projections

Revenue ($M)

1994

CAGR (%)

0.2837

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

3373

2027

4183

2028

4880

2029

5415

2030

5893

2031

6379

2032

6837

Molecule profile

Details & specifications

Molecule

Lutetium (177lu) Vipivotide Tetraxetan

Innovator

NOVARTIS PHARMACEUTICALS CORPORATION

Dosage Form

Intravenous Solution

Strength

27 mCi/mL

Therapeutic Category

Anticancer

Usage

To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.